Knight TherapeuticsFRA:04K 73 Days Payable is 152.99 as of Mar. 2026, which is 1% below its 10-year median of 154.12. GuruFocus rates FRA:04K with a GF Score™ of 73/100 and a GF Value™ of €5.30. The stock has 6 warning signs investors should review. Among 922 Drug Manufacturers companies, Knight Therapeutics ranks better than 77.66% on this metric.
The historical rank and industry rank for Knight Therapeutics's Days Payable or its related term are showing as below:
FRA:04K'
s Days Payable Range Over the Past 10 Years
Min: 92.66 Med: 154.12 Max: 653.7
Current: 159.7
During the past 13 years, Knight Therapeutics's highest Days Payable was 653.70. The lowest was 92.66. And the median was 154.12.
FRA:04K's Days Payable is ranked better than 77.66% of 922
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs FRA:04K: 159.70
Knight Therapeutics's Days Payable
declined
from Mar. 2025 (170.85) to Mar. 2026 (152.99).
It may suggest that Knight Therapeuticsaccelerated paying its suppliers.
Knight Therapeutics Days Payable Related Terms
Knight Therapeutics Days Payable Historical Data
* Premium members only.
The historical data trend for Knight Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Knight Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Knight Therapeutics Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Knight Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Knight Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Knight Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Knight Therapeutics (FRA:04K) has a Days Payable of 152.99 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Knight Therapeutics and its competitors. This is near median its historical median of 154.12. Over the past decade, Knight Therapeutics' Days Payable has ranged from 92.66 to 653.70. According to the industry distribution chart, Knight Therapeutics ranks #206 out of 922 companies in the Drug Manufacturers industry, placing it in the top 22.3%.
Is Knight Therapeutics' Days Payable too high?
Knight Therapeutics' current Days Payable of 152.99 is near median its 10-year median of 154.12. Over the past 10 years, this metric has ranged from a low of 92.66 to a high of 653.70. The Drug Manufacturers industry median Days Payable is 90.84. Knight Therapeutics' value of 152.99 is 68.4% above this industry median. Based on the distribution chart, Knight Therapeutics ranks #206 out of 922 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Knight Therapeutics has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Knight Therapeutics' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Knight Therapeutics ranks #206 out of 922 companies for Days Payable. This places Knight Therapeutics in the top 22% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.84. Knight Therapeutics' value of 152.99 is 68.4% above this benchmark. Historically, Knight Therapeutics' own Days Payable has ranged from 92.66 to 653.70 over the past decade. While the company's 10-year median is 154.12 vs. the industry median of 90.84, Knight Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Knight Therapeutics's current Days Payable of 152.99 is 68.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Knight Therapeutics and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Knight Therapeutics's current Days Payable is 152.99, which is near median its own 10-year median of 154.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Knight Therapeutics stock overvalued right now?
Knight Therapeutics (FRA:04K) has a current Days Payable of 152.99. The stock's GF Value™ is €5.30, compared to a current price of €6.05 — trading 14.2% above its estimated fair value. The current Days Payable is 152.99, which is near median its 10-year median of 154.12 and 68.4% above the Drug Manufacturers industry median of 90.84. Knight Therapeutics' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Knight Therapeutics (FRA:04K), the current Days Payable is 152.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Knight Therapeutics (FRA:04K) Overvalued in 2026?
Based on GuruFocus' analysis, Knight Therapeutics stock appears to be overvalued.
The current stock price of €6.05 is trading 14.2% above its estimated GF Value™ of €5.30.
Key valuation signals for FRA:04K:
Days Payable: 152.99 (near median its 10-year median of 154.12)
GF Value™: €5.30 vs. price of €6.05 (14.2% above fair value)
Industry Position: 68.4% above the Drug Manufacturers median (#206 of 922)
No single metric tells the full story. See the FRA:04K stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and commercializing pharmaceuticalproducts. and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets. The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically, the company generates revenue from Brazil, Canada, Colombia, Argentina, Mexico, Rest of LATAM, and Others, with the majority revenue generated from the Brazil region.
73GF Score
Get the complete analysis for FRA:04K
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:04K has been successfully added to your 
